Each scientific study linking Elmiron to causing night vision damage could help plaintiffs suing Janssen Pharmaceuticals

A Federal judge is examining scientific evidence and will present a list of the experts that can testify at trial in 2022

Tuesday, October 19, 2021 - Scientists at Northwestern University have conducted one of the more credible Elmiron vision loss studies linking taking the anti-interstitial cystitis drug Elmiron (pentosan polysulfate sodium, PPS) with developing a form of eyesight damage called pigmentary maculopathy. The study was published in the Journal of Clinical Ophthalmology and tells readers that people that have taken Elmiron have a form of eyesight damage that produces a unique signature on the back part of the eye called the retina. The study examined 131 patients who had or were taking PPS and examined at the ophthalmology clinic at Northwestern University from 1/1/2002 to 1/1/2019. Forty of the 131 patients were identified to have retinal imaging consistent with maculopathy, and 5 (12.5%) had features suspicious for PPS maculopathy." The study concluded, " A novel drug-induced maculopathy has been associated with PPS use with a distinct clinical constellation that can be accurately identified with multimodal imaging."

According to the study's authors, interstitial cystitis is a painful irritation and inflammation of the inner lining of the bladder. An irritated bladder may often be treated with diet and eliminating spicy foods and caustic beverages like coffee and alcohol. Given the accusations of Elmiron eye problems, IC patients are turning to more holistic treatments for bladder pain like acupuncture and taking super-concentrated Aloe Vera capsules to coat the lining of the bladder.. Urologists have been prescribing Elmiron as it is the only FDA-approved drug to treat IC. Elmiron must be taken for more than three months before enough of it builds up in the blood to alleviate pain. IC affects women predominantly and women complain of having to urinate constantly. Another study had six out of 38 patients testing positive for pigmentary maculopathy. Dove press reports that other studies have produced similar conclusions. "Prospective studies by Wang et al and Vora et al have reported the prevalence of PPS-associated maculopathy to be 20% and 23.1% respectively." The study also suggested that patients taking Elmiron for as short as four months showed signs of PPS-related maculopathy. Another study published in the Journal of Urology found that a high percentage of patients that were taking Elmiron had developed pigmentary maculopathy. Interestingly to note is that most cases of macular degeneration were once considered being due to advancing age when we now know they may have been due to taking Elmiron (PPS). Elmiron continues to be prescribed by urologists in spite of the nasty vision damage in consequences that studies have documented.

Expert witnesses that plaintiffs and the defense intend to call are currently being reviewed by U.S. District Judge Brian Martinotti presiding in New Jersey over hundreds of cases of Elmiron vision damage. Multidistrict litigation saves the court time and money by not having to replicate administrative and discovery processes hundreds of times, and also by selecting only the most credible scientific experts to testify before juries. Elmiron was on the market for over 20 years before Janssen Pharmaceuticals and Johnson & Johnson were forced to update the drug's website to include the warning of causing night blindness.

More Recent Elmiron Eye Lawsuit News:

Lawyers for Elmiron Eye Lawsuits

Attorneys handling Elmiron Eye lawsuits for leukemia, non-Hodgkin lymphoma, and multiple myeloma offer free, no-obligation case review for individuals and families who believe they may have grounds to file a Elmiron Eye lawsuit. Working on a contingency basis, these attorneys are committed to never charging legal fees unless they win compensation in your Elmiron Eye lawsuit. The product liability litigators handling Roundup claims at OnderLaw have a strong track record of success in representing families harmed by dangerous drugs and consumer products.